
Misako Nagasaka, MD, PhD, explains the use of prophylactic anticoagulation for preventing venous thromboembolism (VTE) when administering amivantamab plus lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer. The prophylactic anticoagulation is particularly recommended for the first 4 months of treatment, when the risk of VTE is highest.




